Patient characteristics
| . | Discovery cohort . | Validation cohort . | Control cohort . |
|---|---|---|---|
| Number | 100 | 136 | 100 |
| Patient sex, male/female | 60/40 | 37/99 | 62/38 |
| Ethnic background, white/other/na | 92/6/2 | 128/5/3 | 97/3/0 |
| Transplant type, living/deceased donor | 8/92 | 13/123 | 36/64 |
| Median year of transplantation (range) | 1993 (1988-2004) | 1993 (1988-2004) | 2005 (2004-2007) |
| Median interval transplant to diagnosis of lymphoma, mo (range) | 63 (1-197) | 59(1-201) | |
| Lymphoma localization | |||
| Kidney | 9 (9%) | 9 (6.6%) | |
| Gastrointestinal | 12 (12%) | 16 (12%) | |
| Central nervous system | 4 (4%) | 7 (5%) | |
| Other single site | 53 (53%) | 69 (51%) | |
| Disseminated | 14 (14%) | 15 (11%) | |
| Unknown | 8 (8%) | 20 (15%) | |
| Median age at lymphoma diagnosis, y (range) | 43 (4-72) | 46 (4-73) | |
| Transplanted organ | |||
| Kidney | 100 (100%) | 100 (74%) | 100 (100%) |
| Heart | 24 (24%) | ||
| Liver | 12 (12%) | ||
| Immunosuppression | |||
| Cyclosporine A | 77 (77%) | 114 (84%) | 4 (4%) |
| Tacrolimus | 11 (11%) | 12 (9%) | 94 (94%) |
| Azathioprin | 62 (62%) | 107 (79%) | 13 (13%) |
| Mycophenolate | 14 (14%) | 10 (7%) | 86 (86%) |
| Steroids | 90 (90%) | 126 (92%) | 62 (62%) |
| Rapamycin | 4 (4%) | 2 (2%) | 43 (43%) |
| Antithymocyte globulin | 30 (30%) | 31 (22%) | 11 (11%) |
| Anti-IL2 Ab | 3 (3%) | 9 (7%) | 66 (66%) |
| No data | 4 (4%) | 1 (1%) | 0 (0%) |
| CMV serology | |||
| D−/R− | 27 (27%) | 11 (8%) | 22 (22%) |
| D−/R+ | 18 (18%) | 29 (21%) | 14 (14%) |
| D+/R− | 11 (11%) | 31 (23%) | 24 (24%) |
| D+/R+ | 27 (27%) | 47 (35%) | 39 (39%) |
| na | 17 (17%) | 18 (13%) | 1 (1%) |
| . | Discovery cohort . | Validation cohort . | Control cohort . |
|---|---|---|---|
| Number | 100 | 136 | 100 |
| Patient sex, male/female | 60/40 | 37/99 | 62/38 |
| Ethnic background, white/other/na | 92/6/2 | 128/5/3 | 97/3/0 |
| Transplant type, living/deceased donor | 8/92 | 13/123 | 36/64 |
| Median year of transplantation (range) | 1993 (1988-2004) | 1993 (1988-2004) | 2005 (2004-2007) |
| Median interval transplant to diagnosis of lymphoma, mo (range) | 63 (1-197) | 59(1-201) | |
| Lymphoma localization | |||
| Kidney | 9 (9%) | 9 (6.6%) | |
| Gastrointestinal | 12 (12%) | 16 (12%) | |
| Central nervous system | 4 (4%) | 7 (5%) | |
| Other single site | 53 (53%) | 69 (51%) | |
| Disseminated | 14 (14%) | 15 (11%) | |
| Unknown | 8 (8%) | 20 (15%) | |
| Median age at lymphoma diagnosis, y (range) | 43 (4-72) | 46 (4-73) | |
| Transplanted organ | |||
| Kidney | 100 (100%) | 100 (74%) | 100 (100%) |
| Heart | 24 (24%) | ||
| Liver | 12 (12%) | ||
| Immunosuppression | |||
| Cyclosporine A | 77 (77%) | 114 (84%) | 4 (4%) |
| Tacrolimus | 11 (11%) | 12 (9%) | 94 (94%) |
| Azathioprin | 62 (62%) | 107 (79%) | 13 (13%) |
| Mycophenolate | 14 (14%) | 10 (7%) | 86 (86%) |
| Steroids | 90 (90%) | 126 (92%) | 62 (62%) |
| Rapamycin | 4 (4%) | 2 (2%) | 43 (43%) |
| Antithymocyte globulin | 30 (30%) | 31 (22%) | 11 (11%) |
| Anti-IL2 Ab | 3 (3%) | 9 (7%) | 66 (66%) |
| No data | 4 (4%) | 1 (1%) | 0 (0%) |
| CMV serology | |||
| D−/R− | 27 (27%) | 11 (8%) | 22 (22%) |
| D−/R+ | 18 (18%) | 29 (21%) | 14 (14%) |
| D+/R− | 11 (11%) | 31 (23%) | 24 (24%) |
| D+/R+ | 27 (27%) | 47 (35%) | 39 (39%) |
| na | 17 (17%) | 18 (13%) | 1 (1%) |
D indicates donor; R, recipient; and na, not available.